| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/11/2013 | CA2541869C Compositions and methods for use in targeting vascular destruction |
| 06/11/2013 | CA2520936C An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| 06/11/2013 | CA2513388C Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability |
| 06/11/2013 | CA2498004C Compositions and methods for the diagnosis and treatment of tumor |
| 06/11/2013 | CA2491484C Scanning suspension comprising a particle with a diameter of at least 1 micrometer |
| 06/11/2013 | CA2484209C Protein kinase modulators and methods of use |
| 06/11/2013 | CA2469336C Guanidinium transport reagents and conjugates |
| 06/11/2013 | CA2407959C Human wingless-like gene |
| 06/11/2013 | CA2377381C Neovascular-targeted immunoconjugates |
| 06/11/2013 | CA2312826C Hemiasterlin analogs |
| 06/11/2013 | CA2267664C Human telomerase reverse transcriptase |
| 06/07/2013 | CA2761253A1 Combinations of therapeutic agents for treating melanoma |
| 06/06/2013 | WO2013082563A1 Protein inhibitors to complement and vegf pathways and methods of use thereof |
| 06/06/2013 | WO2013082540A1 Compositions and methods of treating a proliferative disease with a quinazolinone derivative |
| 06/06/2013 | WO2013082511A1 Methods for overcoming tumor resistance to vegf antagonists |
| 06/06/2013 | WO2013082499A1 Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer |
| 06/06/2013 | WO2013082462A1 Amorphous ezatiostat ansolvate |
| 06/06/2013 | WO2013082449A2 Treatment of b cell lymphomas |
| 06/06/2013 | WO2013082389A1 Mmp-targeted therapeutic and/or diagnostic nanocarriers |
| 06/06/2013 | WO2013082366A1 Anti-ceacam1 recombinant antibodies for cancer therapy |
| 06/06/2013 | WO2013082344A1 Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| 06/06/2013 | WO2013082338A1 Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (pmsa) and uses thereof |
| 06/06/2013 | WO2013082324A1 Improved modulators of hec1 activity and methods therefor |
| 06/06/2013 | WO2013082254A1 Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| 06/06/2013 | WO2013082163A1 A ctc biomarker assay to combat breast cancer brain metastasis |
| 06/06/2013 | WO2013082017A1 Cyclized peptidomimetic small molecule inhibitors of the wdr5 and mll1 interaction |
| 06/06/2013 | WO2013081928A2 Method and composition for hyperthermally treating cells |
| 06/06/2013 | WO2013081614A1 Hydroxypolyamine salts |
| 06/06/2013 | WO2013081374A1 Pharmaceutical composition for inhibiting angiogenesis containing plant-derived natural compound |
| 06/06/2013 | WO2013081233A1 Cell killing fusion peptide exhibiting tumor cell-specific necrosis induction and tumor regression |
| 06/06/2013 | WO2013081154A1 Agent for reducing adverse side effects of kinase inhibitor |
| 06/06/2013 | WO2013081091A1 Drug for producing radiolabeled polypeptide reducing non-specific renal accumulation |
| 06/06/2013 | WO2013081046A1 Extract derived from grape rachis |
| 06/06/2013 | WO2013081016A1 Purinone derivative hydrochloride |
| 06/06/2013 | WO2013080187A1 Hpv chimaeric particle |
| 06/06/2013 | WO2013080141A1 Pyrazolopyrrolidine compounds |
| 06/06/2013 | WO2013079980A1 Immunogenic treatment of cancer |
| 06/06/2013 | WO2013079973A1 Antibodies against hgf - receptor and uses |
| 06/06/2013 | WO2013079964A1 Combination treatment of cancer |
| 06/06/2013 | WO2013079687A1 Inkt cell modulators and methods of using the same |
| 06/06/2013 | WO2013079024A1 Oleanolic acid amidate derivatives, preparation methods and uses thereof |
| 06/06/2013 | WO2013079022A1 2-aminated methylene or 2-esterified methylene tanshinone derivatives, and preparation method and application thereof |
| 06/06/2013 | WO2013079018A1 2-substituted oleanolic acid derivative, method preparing for same, and application thereof |
| 06/06/2013 | WO2013079017A1 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof |
| 06/06/2013 | WO2013078973A1 Large particle diameter dasatinib and preparation and use thereof |
| 06/06/2013 | WO2013078771A1 Poly (adp-ribose) polymerase inhibitor |
| 06/06/2013 | WO2013078659A1 Natural ingredients that improve blood vessel elasticity |
| 06/06/2013 | WO2013078554A1 Compositions of tigecycline and uses thereof |
| 06/06/2013 | WO2013078544A1 Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
| 06/06/2013 | WO2013078511A1 Anti-npy and pyy antibodies and uses thereof |
| 06/06/2013 | WO2013059548A9 Compositions and methods for treating cancer using jak2 inhibitor |
| 06/06/2013 | WO2013055913A3 Pgam1 inhibitors and methods related thereto |
| 06/06/2013 | WO2013052699A3 Novel quinoxaline inhibitors of pi3k |
| 06/06/2013 | WO2013051878A3 Antibody specifically binding to epitope in sema domain of c-met |
| 06/06/2013 | WO2013049726A3 Processes for making compounds useful as inhibitors of atr kinase |
| 06/06/2013 | WO2013049521A3 Light-enabled drug delivery |
| 06/06/2013 | WO2013034989A3 Microrna-based methods and assays for osteosarcoma |
| 06/06/2013 | WO2013012771A3 Clinical applications of a recombinant human endostatin adenovirus (e10a) injection |
| 06/06/2013 | WO2012106473A8 Dosing for treatment with anti-egfl7 antibodies |
| 06/06/2013 | WO2012083185A8 Peptide-based in vivo sirna delivery system |
| 06/06/2013 | US20130144056 Human Adam-10 Inhibitors |
| 06/06/2013 | US20130143970 Medicinal preparation particularly for the treatment of slipped discs hernias |
| 06/06/2013 | US20130143919 Pharmaceutical compositions and administrations thereof |
| 06/06/2013 | US20130143316 Nucleic acids molecule encoding the polypeptide for treating virus-induced cancer |
| 06/06/2013 | US20130143281 Chimeric PUFA Polyketide Synthase Systems and Uses Thereof |
| 06/06/2013 | US20130143268 Method of producing the polypeptide for treating virus-induced cancer |
| 06/06/2013 | US20130142864 In vivo targeting of dendritic cells |
| 06/06/2013 | US20130142797 Method of treating virus-induced cancer |
| 06/06/2013 | CA2857747A1 Treatment of b cell lymphomas |
| 06/06/2013 | CA2857712A1 Materials and methods related to nsaid chemoprevention in colorectal cancer |
| 06/06/2013 | CA2857429A1 Immunogenic treatment of cancer |
| 06/06/2013 | CA2857405A1 Poly (adp-ribose) polymerase inhibitor |
| 06/06/2013 | CA2857193A1 Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
| 06/06/2013 | CA2857168A1 Protein inhibitors to complement and vegf pathways and methods of use thereof |
| 06/06/2013 | CA2857155A1 Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| 06/06/2013 | CA2857150A1 Purinone derivative hydrochloride |
| 06/06/2013 | CA2856646A1 Combination treatment of cancer |
| 06/06/2013 | CA2855566A1 Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors |
| 06/06/2013 | CA2854194A1 Mmp-targeted therapeutic and/or diagnostic nanocarriers |
| 06/06/2013 | CA2850293A1 Hpv chimaeric particle |
| 06/06/2013 | CA2762446A1 Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis |
| 06/05/2013 | EP2599868A1 NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO c-Met AND USE THEREOF |
| 06/05/2013 | EP2599504A2 Use of conjugates of fsh receptor ligands and antitumour agents for therapy of cancer |
| 06/05/2013 | EP2599503A2 Polymer conjugates of interferon beta-1A and uses thereof |
| 06/05/2013 | EP2599499A1 Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 06/05/2013 | EP2599497A2 Porphyrazine-chemotherapeutic agents conjugates |
| 06/05/2013 | EP2599495A1 Activin-ActRIIa Antagonists and Uses for Treating or Preventing Breast Cancer |
| 06/05/2013 | EP2598513A1 Compounds and methods for treating neoplasia |
| 06/05/2013 | EP2598512A1 Vinylogous chalcone derivatives and their medical use |
| 06/05/2013 | EP2598508A1 Isoxazolo-quinazolines as modulators of protein kinase activity |
| 06/05/2013 | EP2598507A1 Anticancer derivatives, preparation thereof and therapeutic use thereof |
| 06/05/2013 | EP2598505A2 Substituted imidazo[1,2-b]pyridazines |
| 06/05/2013 | EP2598497A1 Cyclic amine azaheterocyclic carboxamides |
| 06/05/2013 | EP2598492A1 Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k |
| 06/05/2013 | EP2598491A1 Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors |
| 06/05/2013 | EP2598480A1 Cyclopropylamine derivatives useful as lsd1 inhibitors |
| 06/05/2013 | EP2598165A1 Immunogenic anti-inflammatory compositions |
| 06/05/2013 | EP2598147A1 N-methylformamide solvate of dasatinib |
| 06/05/2013 | EP2598144A1 6-(1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-ylthio)-[1,2,4] triazolo [4,3-b] pyridazine as a c-met inhibitor |
| 06/05/2013 | EP2598141A2 Phenylalkyl n-hydroxyureas for treating leukotriene related pathologies |